Market Cap | 2.97B | P/E | - | EPS this Y | 1.70% | Ern Qtrly Grth | - |
Income | -802.69M | Forward P/E | -5.21 | EPS next Y | 19.20% | 50D Avg Chg | 8.00% |
Sales | 328.6M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 13.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -25.00% |
Recommedations | 1.70 | Quick Ratio | 2.46 | Shares Outstanding | 171.85M | 52W Low Chg | 36.00% |
Insider Own | 0.95% | ROA | -24.77% | Shares Float | 160.98M | Beta | 1.11 |
Inst Own | 111.20% | ROE | - | Shares Shorted/Prior | 13.50M/14.87M | Price | 21.77 |
Gross Margin | 77.61% | Profit Margin | -244.27% | Avg. Volume | 979,658 | Target Price | 88.53 |
Oper. Margin | -205.01% | Earnings Date | Oct 24 | Volume | 1,034,090 | Change | -1.63% |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
HC Wainwright & Co. | Buy | Aug 29, 24 |
Truist Securities | Buy | Aug 12, 24 |
HC Wainwright & Co. | Buy | Aug 12, 24 |
TD Cowen | Buy | Aug 9, 24 |
UBS | Buy | Aug 9, 24 |
Stifel | Buy | Aug 9, 24 |
Morgan Stanley | Overweight | Jul 12, 24 |
Goldman Sachs | Buy | Jul 10, 24 |
Guggenheim | Buy | Jul 9, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Wise John Drayton | Chief Commercial Off.. Chief Commercial Officer | Jan 03 | Sell | 29.26 | 21,238 | 621,424 | 115,690 | 01/05/24 |
Wise John Drayton | Chief Commercial Off.. Chief Commercial Officer | Jan 03 | Option | 19.11 | 20,071 | 383,557 | 124,055 | 01/05/24 |
Smith Michael Alexander | General Counsel, Sen.. General Counsel, Senior VP | Jan 04 | Sell | 29.31 | 627 | 18,377 | 88,737 | 01/05/24 |
Schaeffer Orlov S Nicole | Chief People Strateg.. Chief People Strategy Officer | Jan 04 | Sell | 29.28 | 1,457 | 42,661 | 105,149 | 01/05/24 |
Lewis William | Chair and CEO Chair and CEO | Jan 04 | Sell | 29.26 | 6,979 | 204,206 | 373,538 | 01/05/24 |
Flammer Martina M.D. | Chief Medical Office.. Chief Medical Officer | Jan 04 | Sell | 29.21 | 1,386 | 40,485 | 117,525 | 01/05/24 |
Adsett Roger | Chief Operating Offi.. Chief Operating Officer | Jan 04 | Sell | 29.21 | 3,042 | 88,857 | 161,183 | 01/05/24 |
Adsett Roger | Chief Operating Offi.. Chief Operating Officer | Jun 13 | Sell | 19.32 | 8,981 | 173,513 | 151,352 | 06/15/23 |
Wise John Drayton | Chief Commercial Off.. Chief Commercial Officer | Jan 10 | Sell | 17.96 | 779 | 13,991 | 77,272 | 01/12/23 |
Smith Michael Alexander | General Counsel, Sen.. General Counsel, Senior VP | Jan 10 | Sell | 17.93 | 1,836 | 32,919 | 54,332 | 01/12/23 |
Schaeffer Orlov S Nicole | Chief People Strateg.. Chief People Strategy Officer | Jan 10 | Sell | 17.95 | 2,435 | 43,708 | 72,159 | 01/12/23 |
Lewis William | Chair and CEO Chair and CEO | Jan 10 | Sell | 18 | 6,994 | 125,892 | 265,067 | 01/12/23 |
Flammer Martina M.D. | Chief Medical Office.. Chief Medical Officer | Jan 10 | Sell | 18.06 | 3,439 | 62,108 | 72,763 | 01/12/23 |
Bonstein Sara | Chief Financial Offi.. Chief Financial Officer | Jan 10 | Sell | 18.12 | 2,857 | 51,769 | 66,031 | 01/12/23 |
Adsett Roger | Chief Operating Offi.. Chief Operating Officer | Jan 10 | Sell | 17.99 | 3,194 | 57,460 | 135,487 | 01/12/23 |
Wise John Drayton | Chief Commercial Off.. Chief Commercial Officer | Nov 22 | Sell | 18.84 | 7,154 | 134,781 | 71,613 | 11/22/22 |
Adsett Roger | Chief Operating Offi.. Chief Operating Officer | Nov 22 | Sell | 18.80 | 11,855 | 222,874 | 134,127 | 11/22/22 |
SHAROKY MELVIN MD | Director Director | Oct 31 | Buy | 17.62 | 30,000 | 528,600 | 15,900 | 11/02/22 |
LEE LEO | Director Director | Oct 31 | Buy | 17.69 | 45,000 | 796,050 | 98,265 | 11/02/22 |
Smith Michael Alexander | General Counsel, Sen.. General Counsel, Senior VP | Jul 12 | Sell | 23.40 | 941 | 22,019 | 50,455 | 07/12/22 |
Lewis William | Chair and CEO Chair and CEO | Jul 07 | Option | 16.16 | 96,614 | 1,561,282 | 353,330 | 07/08/22 |
Lewis William | Chair and CEO Chair and CEO | Jul 07 | Sell | 23 | 96,614 | 2,222,122 | 256,716 | 07/08/22 |
SHAROKY MELVIN MD | Director Director | May 11 | Buy | 17.2 | 20,000 | 344,000 | 262,621 | 05/13/22 |
Lewis William | Chair and CEO Chair and CEO | Mar 23 | Option | 15.52 | 96,614 | 1,499,449 | 218,605 | 03/25/22 |
Lewis William | Chair and CEO Chair and CEO | Mar 23 | Sell | 23.31 | 96,614 | 2,252,072 | 217,624 | 03/25/22 |
Lewis William | Chair&Chief Executiv.. Chair&Chief Executive Officer | Nov 06 | Option | 6.24 | 235,000 | 1,466,400 | 164,787 | 11/06/20 |
Lewis William | Chair&Chief Executiv.. Chair&Chief Executive Officer | Nov 06 | Sell | 34.08 | 200,000 | 6,816,000 | 129,787 | 11/06/20 |
Pellizzari Christine A | Chief Legal Officer Chief Legal Officer | Nov 05 | Option | 12.19 | 183,450 | 2,236,256 | 134,002 | 11/05/20 |
Pellizzari Christine A | Chief Legal Officer Chief Legal Officer | Nov 05 | Sell | 33.01 | 143,796 | 4,746,706 | 94,348 | 11/05/20 |
SHAROKY MELVIN MD | Director Director | Sep 16 | Sell | 30.69 | 20,000 | 613,800 | 236,890 | 09/16/20 |